{"organizations": [], "uuid": "fadb3c7eb38ecbace9fd319d59bc6d9382174fc3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/evolus-fda/fda-declines-to-approve-evolus-incs-rival-treatment-to-botox-idUSL3N1SN4U4", "country": "US", "domain_rank": 408, "title": "REFILE-FDA declines to approve Evolus Inc's rival treatment to Botox", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-16T15:43:00.000+03:00", "replies_count": 0, "uuid": "fadb3c7eb38ecbace9fd319d59bc6d9382174fc3"}, "author": "", "url": "https://www.reuters.com/article/evolus-fda/fda-declines-to-approve-evolus-incs-rival-treatment-to-botox-idUSL3N1SN4U4", "ord_in_thread": 0, "title": "REFILE-FDA declines to approve Evolus Inc's rival treatment to Botox", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "shailesh kuber", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "evolus inc", "sentiment": "neutral"}, {"name": "allergan plc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "botox reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16, 2018 / 12:42 PM / Updated 16 minutes ago REFILE-FDA declines to approve Evolus Inc's rival treatment to Botox Reuters Staff 1 Min Read\n(Corrects to “Wednesday” from “Tuesday” in paragraph 1)\nMay 16 (Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc’s rival product to Allergan Plc’s Botox, citing certain deficiencies related to its potential treatment for frown lines.\nThe deficiencies cited by the U.S. Food and Drug Administration were isolated to items related to chemistry, manufacturing, and controls processes, the company said.\nNo deficiencies were related to clinical or non-clinical matters, it added. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)", "external_links": [], "published": "2018-05-16T15:43:00.000+03:00", "crawled": "2018-05-16T16:13:33.007+03:00", "highlightTitle": ""}